Special ArticleIncreased survival with β-blockers: Importance of ancillary properties
References (139)
Effect of propranolol in acute myocardial infarction
Lancet
(1965)- et al.
Secondary prevention after myocardial infarction: A review of long-term trials
Prog Cardiovasc Dis
(1982) - et al.
Secondary prevention after myocardial infarction: A review of short-term acute phase trials
Prog Cardiovasc Dis
(1983) - et al.
The role of beta-blockers in the treatment of patients after infarction
Cardiol Clin
(1984) Use of beta blockers in postinfarct prophylaxis: Aspects of quality of life
Am Heart J
(1987)The use of beta-adrenergic blocking agents, IV nitrates and calcium channel blocking agents following acute myocardial infarction
Chest
(1988)- et al.
Guidelines for the early management of patients with acute myocardial infarction
J Am Coll Cardiol
(1990) - et al.
A controlled trial of propranolol in acute myocardial infarction
Lancet
(1966) - et al.
Absence of prophylactic effect of propranolol in myocardial infarction
Lancet
(1966) - et al.
Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results
Lancet
(1974)
Reduction of sudden deaths after myocardial infarction
Lancet
Protective effect of propranolol in threatened myocardial infarction
Lancet
Effect of atenolol on recovery of the electrocardiographic signs of myocardial infarction
Lancet
Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results
Lancet
Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction
Lancet
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial
Lancet
Controlled trial of sotalol for one year after myocardial infarction
Lancet
Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol
J Pharmacol Exp Ther
Goth's Medical Pharmacology
Secondary prevention of acute myocardial infarction with beta-blocking agents and calcium antagonists
Am J Cardiol
Beta-blockers in the treatment of myocardial infarction
Br Med J
Beta blocking agents: Current status in the prevention of sudden coronary death
Ann NY Acad Sci
Confidence in results of beta-blocker postinfarction trials
Br Med J
Beta-blockade and acute myocardial infarction
Eur Heart J
Interventions during and after myocardial infarction
Postgrad Med J
The use of β-blockers after myocardial infarction
JAMA
Beta blockers in ischemic heart disease
Am J Cardiol
A review of acute-phase beta-blocker trials in patients with myocardial infarction
Circulation
Improved prognosis during long-term treatment with beta-blockers after myocardial infarction: Analysis of randomized trials and pooling of results
Cardiol Clin Care
Beta-blockade during and after myocardial infarction: an overview of the randomized trials
Prog Cardiovasc Dis
Use of beta-adrenergic blocking agents after myocardial infarction
Postgrad Med
Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1
Lancet
Secondary prevention after myocardial infarction: Effects of beta blocking agents and calcium antagonists
Cardiovasc Drugs Ther
Early intravenous beta-blockade in acute myocardial infarction
Cardiology
Diuretic agents versus beta-blockers: Comparison of effects on mortality, stroke, and coronary events
Hypertension
Review of beta-blocker myocardial infarction trials
Clin Cardiol
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction
Am J Cardiol
Importance of heart rate on determining beta blocker efficacy in acute and long-term acute myocardial infarction intervention trials
Am J Cardiol
A meta-analysis of mortality and coronary prevention in hypertensive patients treated with beta-receptor blockers
J Hum Hypertens
Beta-blockers and primary cardioprotection in hypertension
Drugs Exp Clin Res
Primary prevention with β-blockade in patients with hypertension: Review of results and clinical implications
J Cardiovasc Pharmacol
Myocardial infarction: Effects of beta-blockade
Circulation
β-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence
Circulation
Primary prevention with metoprolol in hypertensive patients
Progr Hypertens
A comparison of results of meta-analysis of randomized controlled trials and recommendations of clinical experts. Treatments for myocardial infarction
JAMA
Cumulative meta-analysis of therapeutic trials for myocardial infarction
N Engl J Med
Metoprolol induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials
Eur Heart J
Management of elderly patients with sustained hypertension
Br Med J
Effects of beta-blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects
Am J Cardiol
Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated, controlled trials
J Hypertens
Cited by (73)
Study on the inclusion behavior of p-sulfonatocalix[6]arene with propranolol by spectrofluorometry
2012, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyCitation Excerpt :Propranolol (PPL, Fig. 1a), a class of β-adrenergic blocking drugs, is widely used as standard therapy in the treatment of hypertension, angina pectoris, cardiac arrhythmias and hypertrophic subaortic stenosis [21,22]. When administered chronically, it reduces the mortality due to hypertension and lengthens survival in patients with coronary heart disease [23,24]. However, it was shown that the release of PPL was cumbered at higher pH of small intestine owing to the pH-dependent solubility [25].
The role of the new β-blockers in treating cardiovascular disease
2005, American Journal of HypertensionEffects of β-adrenoceptor antagonists in the neural nitric oxide release induced by electrical field stimulation and sodium channel activators in the rabbit corpus cavernosum
2005, European Journal of PharmacologyCitation Excerpt :It is well established that β-adrenoceptors are widely distributed in mammalian tissues both at post- and pre-synaptic levels. In addition to their ability to antagonize β-receptors, β-adrenoceptor antagonists possess ancillary properties that may modulate their clinical effects, such as inhibition of Ca2+ channels, lipophilicity and membrane-stabilizing activity (Soriano et al., 1997; Kostis and Rosen, 1987). Considering that the β1-adrenoceptor antagonists used in this study are equally effective to antagonize the β1-receptors at the post-synaptic level (Nakane et al., 1988; Chiba and Tsukada, 1991; Longhurst and Levendusky, 1999; Mustafa et al., 1999), it is likely that inhibition of Ts3-, Ts1- and brevetoxin-3-induced relaxations by these compounds reflect β1-independent activities, such as these ancillary properties.
Clinical pharmacology of antihypertensive therapy
2005, Seminars in NephrologyCardiovascular drug class specificity: β-blockers
2004, Progress in Cardiovascular DiseasesSympatho-modulatory therapies in perioperative medicine
2004, British Journal of AnaesthesiaCitation Excerpt :Importantly, induction of thoracic epidural anaesthesia during maximal metoprolol treatment did not cause any further haemodynamic changes (particularly no further decline in arterial pressure). Similarly, in a clinical study evaluating the effect of thoracic epidural anaesthesia (T1-T12) on cardiovascular function in patients with coronary artery disease receiving β-AAs, no further cardiac depression (decrease in arterial pressure and heart rate) occurred.76 From this, it can be speculated that the favourable haemodynamic effects of thoracic epidural anaesthesia may be synergistic with the documented life-saving effects of β-AAs.